Clinical Report: Shingles Vaccine Tied to Slower Aging
Overview
Shingles vaccination in adults aged 70 years or older is associated with slower epigenetic and transcriptomic aging, with effects persisting beyond three years post-vaccination. The study highlights lower inflammation scores and improved biological aging profiles among vaccinated individuals compared to their unvaccinated counterparts.
Background
The relationship between vaccination and biological aging is an emerging area of research that may influence public health strategies for older adults. Understanding how vaccines like the shingles vaccine can impact aging processes is crucial, especially as the population ages and the burden of age-related diseases increases. This study adds to the evidence suggesting that vaccines may contribute to healthier aging outcomes.
Data Highlights
No numerical data available in the provided material.
Key Findings
- Shingles vaccination is linked to lower inflammation scores in older adults.
- Vaccinated individuals exhibited slower epigenetic and transcriptomic aging.
- Associations with biological aging measures persisted beyond three years post-vaccination.
- Higher adaptive immunity scores were observed in vaccinated individuals, indicating a complex immune response.
- Composite biological aging scores were lower in vaccinated adults compared to unvaccinated peers.
- Potential limitations include self-reported vaccination status and cross-sectional biomarker data.
Clinical Implications
Healthcare professionals should consider the potential benefits of shingles vaccination beyond infection prevention, particularly in promoting healthier aging in older adults. The findings may support vaccination as part of comprehensive geriatric care strategies aimed at reducing inflammation and improving overall biological aging profiles.
Conclusion
The study underscores the importance of shingles vaccination in older adults, suggesting it may play a role in mitigating biological aging processes. Further research is warranted to explore these associations and their implications for public health.
References
- KFF Health News, 2023 -- Vaccines May Do More for Aging Bodies
- The Journal of Infectious Diseases, 2023 -- High-Dose Inactivated Influenza Vaccine Inconsistently Improves Heterologous Antibody Responses in an Older Human Cohort
- UCI Health, 2024 -- Shingles nearly took his sight but UCI Health saved it
- Frontiers in Immunology, 2026 -- Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study
- CDC, 2023 -- Shingles Vaccine Recommendations | Shingles (Herpes Zoster)
- PubMed, 2023 -- Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications
- FDA, 2023 -- FDA Requires a Warning about Guillain-Barré Syndrome (GBS) be Included in the Prescribing Information for Shingrix
- Shingles Vaccine Recommendations | Shingles (Herpes Zoster) | CDC
- Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications - PubMed
- FDA Requires a Warning about Guillain-Barré Syndrome (GBS) be Included in the Prescribing Information for Shingrix | FDA
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
